Skip to main content
. 2019 May 27;37(9):1155–1163. doi: 10.1007/s40273-019-00810-8

Table 1.

Example calculation of the severity-weighted cost effectiveness

Model run (s) Disease burden calculation Model results Combined results
QALE patients (Qd) QALE general population with same age and gender (Qn) Absolute shortfall (Qn − Qd) Proportional shortfall [(Qn − Qd)/Qn)] Applicable threshold (Vs) Incremental costs, € (∆C) Incremental benefits (∆Q) ICER, € (∆C/∆Q) INMB, € (∆Q × Vs − ∆C) Cost-effective?a
1 15 25 10 0.40 20,000 20,000 0.60 33,333 − 8000.00 0
2 16 24 8 0.33 20,000 8000 0.50 16,000 2000.00 1
3 17 28 11 0.39 20,000 15,000 0.60 25,000 − 3000.00 0
4 15 28 13 0.46 50,000 10,000 0.50 20,000 15,000.00 1
5 14 27 13 0.48 50,000 10,000 0.40 25,000 10,000.00 1
6 13 26 13 0.50 50,000 25,000 0.30 83,333 − 10,000.00 0
7 15 26 11 0.42 20,000 25,000 0.60 41,667 − 13,000.00 0
8 15 32 17 0.53 50,000 15,000 0.50 30,000 10,000.00 1
9 16 25 9 0.36 20,000 25,000 0.60 41,667 − 13,000.00 0
10 16 26 10 0.38 20,000 20,000 0.80 25,000 − 4000.00 0
Severity weighted probability of being cost effective 40%

ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, QALE quality-adjusted life expectancy

a1 = Yes